An Introduction to Viral Vectors: Safety Considerations
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Non-Primate Lentiviral Vectors and Their Applications in Gene Therapy for Ocular Disorders
viruses Review Non-Primate Lentiviral Vectors and Their Applications in Gene Therapy for Ocular Disorders Vincenzo Cavalieri 1,2,* ID , Elena Baiamonte 3 and Melania Lo Iacono 3 1 Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze Edificio 16, 90128 Palermo, Italy 2 Advanced Technologies Network (ATeN) Center, University of Palermo, Viale delle Scienze Edificio 18, 90128 Palermo, Italy 3 Campus of Haematology Franco e Piera Cutino, Villa Sofia-Cervello Hospital, 90146 Palermo, Italy; [email protected] (E.B.); [email protected] (M.L.I.) * Correspondence: [email protected] Received: 30 April 2018; Accepted: 7 June 2018; Published: 9 June 2018 Abstract: Lentiviruses have a number of molecular features in common, starting with the ability to integrate their genetic material into the genome of non-dividing infected cells. A peculiar property of non-primate lentiviruses consists in their incapability to infect and induce diseases in humans, thus providing the main rationale for deriving biologically safe lentiviral vectors for gene therapy applications. In this review, we first give an overview of non-primate lentiviruses, highlighting their common and distinctive molecular characteristics together with key concepts in the molecular biology of lentiviruses. We next examine the bioengineering strategies leading to the conversion of lentiviruses into recombinant lentiviral vectors, discussing their potential clinical applications in ophthalmological research. Finally, we highlight the invaluable role of animal organisms, including the emerging zebrafish model, in ocular gene therapy based on non-primate lentiviral vectors and in ophthalmology research and vision science in general. Keywords: FIV; EIAV; BIV; JDV; VMV; CAEV; lentiviral vector; gene therapy; ophthalmology; zebrafish 1. -
An Overview of the Molecular Phylogeny of Lentiviruses
Phylogeny of Lentiviruses 35 An overview of the molecular Reviews phylogeny of lentiviruses Brian T. Foley T10, MS K710, Los Alamos National Laboratory, Los Alamos, NM 87545 Introduction Lentiviruses are one of several groups of retroviruses. In early studies of the molecular phylogenetic analysis of endogenous and exogenous retroviruses it was suggested that the retroviruses could be divided into four groups, two complex with several accessory or regulatory genes (lentiviruses; and the bovine and primate leukemia virus group now known as deltaretrovirus) and two simple, with just the gag, pol and env genes and few or no accessory genes (a group including spumaretroviruses, C-type endogenous retroviruses and MMLV; the other group including Rous Sarcoma virus, HERV-K Simian Retrovirus 1 and MMTV) [1–5]. A more recent study, including many more recently discovered exogenous and endogenous retroviruses, illustrates the diversity of retroviruses [6]. The retroviridae are currently officially classified into seven different genera, according to the Seventh Report of the International Committee on Taxonomy of Viruses, 2000 (http://www.ncbi.nlm.nih.gov/ICTV). The seven genera are named alpha through epsilon retroviruses plus lentiviruses and spumaviruses. Phylogenetic trees based on pol gene sequences can be found in several recent papers[6–8]. None of the retroviruses in either group of complex retroviruses have been found in an endogenous state to date. Within the Lentiviruses, the primate lentiviruses discovered to date form a monophyletic cluster (Figure 1). One notable difference between the primate lentiviruses and the non-primate lentiviruses is that all nonprimate lentiviruses, except the BIV/JDV lineage, contain a region of the pol gene encoding a dUTPase, whereas all primate lentiviruses lack this region of pol. -
Mobile Genetic Elements in Streptococci
Curr. Issues Mol. Biol. (2019) 32: 123-166. DOI: https://dx.doi.org/10.21775/cimb.032.123 Mobile Genetic Elements in Streptococci Miao Lu#, Tao Gong#, Anqi Zhang, Boyu Tang, Jiamin Chen, Zhong Zhang, Yuqing Li*, Xuedong Zhou* State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, PR China. #Miao Lu and Tao Gong contributed equally to this work. *Address correspondence to: [email protected], [email protected] Abstract Streptococci are a group of Gram-positive bacteria belonging to the family Streptococcaceae, which are responsible of multiple diseases. Some of these species can cause invasive infection that may result in life-threatening illness. Moreover, antibiotic-resistant bacteria are considerably increasing, thus imposing a global consideration. One of the main causes of this resistance is the horizontal gene transfer (HGT), associated to gene transfer agents including transposons, integrons, plasmids and bacteriophages. These agents, which are called mobile genetic elements (MGEs), encode proteins able to mediate DNA movements. This review briefly describes MGEs in streptococci, focusing on their structure and properties related to HGT and antibiotic resistance. caister.com/cimb 123 Curr. Issues Mol. Biol. (2019) Vol. 32 Mobile Genetic Elements Lu et al Introduction Streptococci are a group of Gram-positive bacteria widely distributed across human and animals. Unlike the Staphylococcus species, streptococci are catalase negative and are subclassified into the three subspecies alpha, beta and gamma according to the partial, complete or absent hemolysis induced, respectively. The beta hemolytic streptococci species are further classified by the cell wall carbohydrate composition (Lancefield, 1933) and according to human diseases in Lancefield groups A, B, C and G. -
Chapitre Quatre La Spécificité D'hôtes Des Virophages Sputnik
AIX-MARSEILLE UNIVERSITE FACULTE DE MEDECINE DE MARSEILLE ECOLE DOCTORALE DES SCIENCES DE LA VIE ET DE LA SANTE THESE DE DOCTORAT Présentée par Morgan GAÏA Né le 24 Octobre 1987 à Aubagne, France Pour obtenir le grade de DOCTEUR de l’UNIVERSITE AIX -MARSEILLE SPECIALITE : Pathologie Humaine, Maladies Infectieuses Les virophages de Mimiviridae The Mimiviridae virophages Présentée et publiquement soutenue devant la FACULTE DE MEDECINE de MARSEILLE le 10 décembre 2013 Membres du jury de la thèse : Pr. Bernard La Scola Directeur de thèse Pr. Jean -Marc Rolain Président du jury Pr. Bruno Pozzetto Rapporteur Dr. Hervé Lecoq Rapporteur Faculté de Médecine, 13385 Marseille Cedex 05, France URMITE, UM63, CNRS 7278, IRD 198, Inserm 1095 Directeur : Pr. Didier RAOULT Avant-propos Le format de présentation de cette thèse correspond à une recommandation de la spécialité Maladies Infectieuses et Microbiologie, à l’intérieur du Master des Sciences de la Vie et de la Santé qui dépend de l’Ecole Doctorale des Sciences de la Vie de Marseille. Le candidat est amené à respecter des règles qui lui sont imposées et qui comportent un format de thèse utilisé dans le Nord de l’Europe permettant un meilleur rangement que les thèses traditionnelles. Par ailleurs, la partie introduction et bibliographie est remplacée par une revue envoyée dans un journal afin de permettre une évaluation extérieure de la qualité de la revue et de permettre à l’étudiant de commencer le plus tôt possible une bibliographie exhaustive sur le domaine de cette thèse. Par ailleurs, la thèse est présentée sur article publié, accepté ou soumis associé d’un bref commentaire donnant le sens général du travail. -
Guide for Common Viral Diseases of Animals in Louisiana
Sampling and Testing Guide for Common Viral Diseases of Animals in Louisiana Please click on the species of interest: Cattle Deer and Small Ruminants The Louisiana Animal Swine Disease Diagnostic Horses Laboratory Dogs A service unit of the LSU School of Veterinary Medicine Adapted from Murphy, F.A., et al, Veterinary Virology, 3rd ed. Cats Academic Press, 1999. Compiled by Rob Poston Multi-species: Rabiesvirus DCN LADDL Guide for Common Viral Diseases v. B2 1 Cattle Please click on the principle system involvement Generalized viral diseases Respiratory viral diseases Enteric viral diseases Reproductive/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 2 Deer and Small Ruminants Please click on the principle system involvement Generalized viral disease Respiratory viral disease Enteric viral diseases Reproductive/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 3 Swine Please click on the principle system involvement Generalized viral diseases Respiratory viral diseases Enteric viral diseases Reproductive/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 4 Horses Please click on the principle system involvement Generalized viral diseases Neurological viral diseases Respiratory viral diseases Enteric viral diseases Abortifacient/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 5 Dogs Please click on the principle system involvement Generalized viral diseases Respiratory viral diseases Enteric viral diseases Reproductive/neonatal viral diseases Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. -
Gutless Adenovirus: Last-Generation Adenovirus for Gene Therapy
Gene Therapy (2005) 12, S18–S27 & 2005 Nature Publishing Group All rights reserved 0969-7128/05 $30.00 www.nature.com/gt CONFERENCE PAPER Gutless adenovirus: last-generation adenovirus for gene therapy R Alba1, A Bosch1 and M Chillon1,2 1Gene Therapy Laboratory, Department of Biochemistry and Molecular Biology, Center of Animal Biotechnology and Gene Therapy (CBATEG), Universitat Auto`noma de Barcelona, Bellaterra, Spain; and 2Institut Catala` de Recerca i Estudis Avanc¸ats (ICREA), Barcelona, Spain Last-generation adenovirus vectors, also called helper-depen- viral coding regions, gutless vectors require viral proteins dent or gutless adenovirus, are very attractive for gene therapy supplied in trans by a helper virus. To remove contamination because the associated in vivo immune response is highly by a helper virus from the final preparation, different systems reduced compared to first- and second-generation adenovirus based on the excision of the helper-packaging signal have vectors, while maintaining high transduction efficiency and been generated. Among them, Cre-loxP system is mostly tropism. Nowadays, gutless adenovirus is administered in used, although contamination levels still are 0.1–1% too high different organs, such as the liver, muscle or the central to be used in clinical trials. Recently developed strategies to nervous system achieving high-level and long-term transgene avoid/reduce helper contamination were reviewed. expression in rodents and primates. However, as devoid of all Gene Therapy (2005) 12, S18–S27. doi:10.1038/sj.gt.3302612 Keywords: adenovirus; gutless; helper-dependent vectors; in vivo gene therapy Introduction clinical for more information). Nowadays, adenovirus vectors are applied to treat cancer, monogenic disorders, Gene therapy for most genetic diseases requires expres- vascular diseases and others complications. -
The Expression of Human Endogenous Retroviruses Is Modulated by the Tat Protein of HIV‐1
The Expression of Human Endogenous Retroviruses is modulated by the Tat protein of HIV‐1 by Marta Jeannette Gonzalez‐Hernandez A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Immunology) in The University of Michigan 2012 Doctoral Committee Professor David M. Markovitz, Chair Professor Gary Huffnagle Professor Michael J. Imperiale Associate Professor David J. Miller Assistant Professor Akira Ono Assistant Professor Christiane E. Wobus © Marta Jeannette Gonzalez‐Hernandez 2012 For my family and friends, the most fantastic teachers I have ever had. ii Acknowledgements First, and foremost, I would like to thank David Markovitz for his patience and his scientific and mentoring endeavor. My time in the laboratory has been an honor and a pleasure. Special thanks are also due to all the members of the Markovitz laboratory, past and present. It has been a privilege, and a lot of fun, to work near such excellent scientists and friends. You all have a special place in my heart. I would like to thank all the members of my thesis committee for all the valuable advice, help and jokes whenever needed. Our collaborators from the Bioinformatics Core, particularly James Cavalcoli, Fan Meng, Manhong Dai, Maureen Sartor and Gil Omenn gave generous support, technical expertise and scientific insight to a very important part of this project. Thank you. Thanks also go to Mariana Kaplan’s and Akira Ono’s laboratory for help with experimental designs and for being especially generous with time and reagents. iii Table of Contents Dedication ............................................................................................................................ ii Acknowledgements ............................................................................................................. iii List of Figures ................................................................................................................... -
Viral Vectors and Biological Safety
Viral Vectors and Biological Safety Viral vectors are often designed so that they can enter human cells and deliver genes of interest. Viral vectors are usually replication-deficient – genes necessary for replication of the virus are removed from the vector and supplied separately through plasmids, helper virus, or packaging cell lines. There are several biosafety concerns that arise with the use of viral vectors including: 1) Tropism (host range) – viral vectors that can enter (infect) human cells are often used. 2) Replication-deficient viral vectors can gain back the deleted genes required for replication (become replication-competent) through recombination – referred to as replication-competent virus (RCV) breakthroughs. 3) Genes may be expressed in tissues and/or organisms where they are normally not expressed. In the case of some genes such as oncogenes, this could have far-reaching negative consequences. When evaluating safety for use of viral vectors, a number of factors need to be considered including: Risk Group (RG) of the organism; tropism (organism and tissue); route of transmission; whether the virus integrates into the host genome; and the specific gene(s) being introduced. Please contact the Office of Biological Safety (OBS) for more information on physical barriers and safety practices to use with specific viral vectors. This article concentrates on biological barriers that can be employed to improve safety when using viral vectors. Viral vectors frequently used are: • Retrovirus/lentivirus • Adenovirus • Adeno-associated virus (AAV) • Poxvirus • Herpes virus • Alphavirus • Baculovirus Amphotropic murine leukemia virus (MLV) – also called Moloney murine leukemia virus (MMLV) – and adenovirus are common viral vectors used to introduce genes into human cells. -
Replication-Defective Chimeric Helper Proviruses and Factors Affecting Generation of Competent Virus
MOLECULAR AND CELLULAR BIOLOGY, May 1987, p. 1797-1806 Vol. 7, No. 5 0270-7306/87/051797-10$02.00/0 Copyright © 1987, American Society for Microbiology Replication-Defective Chimeric Helper Proviruses and Factors Affecting Generation of Competent Virus: Expression of Moloney Murine Leukemia Virus Structural Genes via the Metallothionein Promoter ROBERT A. BOSSELMAN,* ROU-YIN HSU, JOAN BRUSZEWSKI, SYLVIA HU, FRANK MARTIN, AND MARGERY NICOLSON Amgen, Thousand Oaks, California 91320 Received 15 October 1986/Accepted 28 January 1987 Two chimeric helper proviruses were derived from the provirus of the ecotropic Moloney murine leukemia virus by replacing the 5' long terminal repeat and adjacent proviral sequences with the mouse metallothionein I promoter. One of these chimeric proviruses was designed to express the gag-pol genes of the virus, whereas the other was designed to express only the env gene. When transfected into NIH 3T3 cells, these helper proviruses failed to generate competent virus but did express Zn2 -inducible trans-acting viral functions needed to assemble infectious vectors. One helper cell line (clone 32) supported vector assembly at levels comparable to those supported by the Psi-2 and PA317 cell lines transfected with the same vector. Defective proviruses which carry the neomycin phosphotransferase gene and which lack overlapping sequence homology with the 5' end of the chimeric helper proviruses could be transfected into the helper cell line without generation of replication-competent virus. Mass cultures of transfected helper cells produced titers of about 104 G418r CFU/ml, whereas individual clones produced titers between 0 and 2.6 x 104 CFU/ml. -
DNA Recombination Is Sufficient for Retroviral Transduction JODY R
Proc. Natl. Acad. Sci. USA Vol. 92, pp. 2460-2464, March 1995 Biochemistry DNA recombination is sufficient for retroviral transduction JODY R. SCHWARTZ, Susi DUESBERG, AND PETER H. DUESBERG Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720-3206 Contributed by Peter H. Duesberg, November 28, 1994 ABSTRACT Oncogenic retroviruses carry coding se- quences that are transduced from cellular protooncogenes. Nat- env pOl X ural transduction involves two nonhomologous recombinations and is thus extremely rare. Since transduction has never been reproduced experimentall, its mechanism has been studied in terms oftwoehypotheses: (i) the DNAmodel,which postulates two ___ _-I ____ DNA recombinations, and (ii) the RNA model, which postulates a 5' DNA recombination and a 3' RNA recombination occurring during reverse transcription of viral and protooncogene RNA. proto-onc gene Here we use two viral DNA constructs to test the prediction ofthe DNA model that the 3' DNA recombination is achieved by conventional integration of a retroviral DNA 3' of the chromo- somal protooncogene coding region. For the DNA model to be ga-onc - gag viable, such recombinant viruses must be infectious without the w5 essential tract that precedes the 3' purportedly polypurine (ppt) FIG. 1. The DNA model of retroviral transduction. The model long terminal repeat (LTR) of all retroviruses. Our constructs proposes that the 5' retrovirus/protooncogene junction is achieved by consist ofa ras coding region from Harvey sarcoma virus which nonhomologous recombination between a circular provirus with a is naturally linked at the 5' end to a retroviral LTR and single LTR. Such proviruses are common in virus-infected cells (1). -
Enhancement of Antitumor Activity of Gammaretrovirus Carrying IL-12
Cancer Gene Therapy (2010) 17, 37–48 r 2010 Nature Publishing Group All rights reserved 0929-1903/10 $32.00 www.nature.com/cgt ORIGINAL ARTICLE Enhancement of antitumor activity of gammaretrovirus carrying IL-12 gene through genetic modification of envelope targeting HER2 receptor: a promising strategy for bladder cancer therapy Y-S Tsai1,2,3, A-L Shiau1,4, Y-F Chen4, H-T Tsai3, T-S Tzai3 and C-L Wu1,5 1Institute of Clinical Medicine, National Cheng Kung University Medical College, Tainan, Taiwan; 2Department of Urology, National Cheng Kung University Hospital, Dou-Liou Branch, Yunlin, Taiwan; 3Department of Urology, National Cheng Kung University Medical College, Tainan, Taiwan; 4Department of Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan and 5Department of Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan The objective of this study was to develop an HER2-targeted, envelope-modified Moloney murine leukemia virus (MoMLV)-based gammaretroviral vector carrying interleukin (IL)-12 gene for bladder cancer therapy. It displayed a chimeric envelope protein containing a single-chain variable fragment (scFv) antibody to the HER2 receptor and carried the mouse IL-12 gene. The fragment of anti-erbB2scFv was constructed into the proline-rich region of the viral envelope of the packaging vector lacking a transmembrane subunit of the carboxyl terminal region of surface subunit. As compared with envelope-unmodified gammaretroviruses, envelope- modified ones -
Toll-Like Receptor and Cytokine Responses to Infection with Endogenous and Exogenous Koala Retrovirus, and Vaccination As a Control Strategy
Review Toll-Like Receptor and Cytokine Responses to Infection with Endogenous and Exogenous Koala Retrovirus, and Vaccination as a Control Strategy Mohammad Enamul Hoque Kayesh 1,2 , Md Abul Hashem 1,3,4 and Kyoko Tsukiyama-Kohara 1,4,* 1 Transboundary Animal Diseases Centre, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima 890-0065, Japan; [email protected] (M.E.H.K.); [email protected] (M.A.H.) 2 Department of Microbiology and Public Health, Faculty of Animal Science and Veterinary Medicine, Patuakhali Science and Technology University, Barishal 8210, Bangladesh 3 Department of Health, Chattogram City Corporation, Chattogram 4000, Bangladesh 4 Laboratory of Animal Hygiene, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima 890-0065, Japan * Correspondence: [email protected]; Tel.: +81-99-285-3589 Abstract: Koala populations are currently declining and under threat from koala retrovirus (KoRV) infection both in the wild and in captivity. KoRV is assumed to cause immunosuppression and neoplastic diseases, favoring chlamydiosis in koalas. Currently, 10 KoRV subtypes have been identified, including an endogenous subtype (KoRV-A) and nine exogenous subtypes (KoRV-B to KoRV-J). The host’s immune response acts as a safeguard against pathogens. Therefore, a proper understanding of the immune response mechanisms against infection is of great importance for Citation: Kayesh, M.E.H.; Hashem, the host’s survival, as well as for the development of therapeutic and prophylactic interventions. M.A.; Tsukiyama-Kohara, K. Toll-Like A vaccine is an important protective as well as being a therapeutic tool against infectious disease, Receptor and Cytokine Responses to Infection with Endogenous and and several studies have shown promise for the development of an effective vaccine against KoRV.